Drug Eluting Stents, Bare Metal Stents: No Survival Difference
Stefan James
Raymond Gibbons
REFERENCE: Hot Line 1 Sunday 11:00 2 Sept, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
STEFAN JAMES, Uppsala Clinical Research Centre, Sweden
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN
Another year’s results of the long term outcome of using drug-eluting stents as compared with bare-metal stents from Sweden reveal that there is no longer an increased risk of late mortality when using drug-eluting stents according to Stefan James of Uppsala Clinical Research Centre. He suggested that improvements in technique have helped reduce the risk of death or myocardial infarction associated with using drug-eluting stents nevertheless the risk of blood clots still remains. Overall survival of patients was found to be the similar for both categories of stent.
Nicola Soloman interviewed Stefan James after his presentation at the European Society of Cardiology meeting in Vienna. Raymond Gibbons, president of the American Heart Association, added his comments.
STEFAN JAMES, Uppsala Clinical Research Centre, Sweden
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN
Another year’s results of the long term outcome of using drug-eluting stents as compared with bare-metal stents from Sweden reveal that there is no longer an increased risk of late mortality when using drug-eluting stents according to Stefan James of Uppsala Clinical Research Centre. He suggested that improvements in technique have helped reduce the risk of death or myocardial infarction associated with using drug-eluting stents nevertheless the risk of blood clots still remains. Overall survival of patients was found to be the similar for both categories of stent.
Nicola Soloman interviewed Stefan James after his presentation at the European Society of Cardiology meeting in Vienna. Raymond Gibbons, president of the American Heart Association, added his comments.
